US 11,970,500 B1
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
Zhiwei Wang, Beijing (CN); Yunhang Guo, Beijing (CN); Gongyin Shi, Beijing (CN); and Lai Wang, Beijing (CN)
Assigned to BeiGene Switzerland GmbH, Basel (CH)
Filed by BEIGENE SWITZERLAND GMBH, Basel (CH)
Filed on Dec. 1, 2023, as Appl. No. 18/526,535.
Application 18/526,535 is a continuation of application No. 17/858,826, filed on Jul. 6, 2022, granted, now 11,884,674.
Application 17/858,826 is a continuation of application No. 17/146,855, filed on Jan. 12, 2021.
Application 17/146,855 is a continuation of application No. 16/325,447, granted, now 10,927,117, issued on Feb. 23, 2021, previously published as PCT/IB2017/054955, filed on Aug. 15, 2017.
Claims priority of application No. PCT/CN2016/09510 (WO), filed on Aug. 16, 2016.
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07B 2200/13 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A method for treating a B-cell proliferative disease in a subject, comprising administering to the subject in need thereof Compound 1,

OG Complex Work Unit Chemistry
wherein the B-cell proliferative disease is selected from a group consisting of chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, and follicular lymphoma; and
Compound 1 is administrated at a dose of 320 mg once a day (QD).